For many of us, the phrase “virus outbreak on a cruise ship” triggers an immediate, visceral memory: the Ruby Princess docking in Sydney in March 2020. That moment served as a grim harbinger of the COVID-19 pandemic, as 575 passengers and crew disembarked, carrying a virus that would soon dismantle global norms and claim millions of lives. It is entirely understandable, then, why the news of passengers from the MV Hondius requiring quarantine after potential exposure to the Andes virus has sparked a wave of anxiety.
But as a physician, I want to offer a necessary piece of clinical perspective: the comparison between the Andes virus and SARS-CoV-2 ends incredibly quickly. While the Andes virus is a serious pathogen—and authorities are right to respond with cautious rigor—it lacks the fundamental biological “engine” required to trigger a global pandemic. To understand why, we have to look past the headlines and into the specific way this virus interacts with the human body and the environment.
As of May 11, European health authorities have reported nine cases linked to the MV Hondius, including seven confirmed and two probable cases, with three deaths reported. In response, five Australians and one New Zealander are being repatriated to Australia for strict monitoring at the Centre for National Resilience near RAAF Base Pearce in Western Australia. While these numbers are sobering, they represent a contained cluster, not the start of a global surge.
The Transmission Gap: Why Deadliness Does Not Equal Pandemic Potential
The most critical distinction between the Andes virus and COVID-19 is how they move from person to person. Hantaviruses, as a group, are typically zoonotic, meaning they jump from animals to humans. They are carried by rodents, and humans usually become infected by inhaling aerosolized particles of contaminated urine, droppings, or saliva—often while cleaning out an old shed or exploring a rodent-infested area.
The Andes virus is a rare exception in the hantavirus family because it has well-documented person-to-person transmission. However, “possible” does not mean “efficient.” For the Andes virus to spread between humans, it requires what epidemiologists call a “perfect storm” of conditions: symptomatic individuals in crowded, poorly ventilated spaces with prolonged, close contact. This is precisely what occurred on the MV Hondius, creating a localized environment where the virus could jump.
Contrast this with SARS-CoV-2. COVID-19 is a master of efficiency. It spreads rapidly through the air, often before an infected person even realizes they are sick. Early estimates showed that in a naive population, one person could easily infect two or more others. The Andes virus does not possess this capability. It is a slow-burning fire compared to the wildfire of COVID-19.
| Feature | Andes Virus (Hantavirus) | SARS-CoV-2 (COVID-19) |
|---|---|---|
| Primary Spread | Rodent excreta; rare close human contact | Highly efficient airborne transmission |
| Incubation Period | Long (up to several weeks) | Short (typically 2–14 days) |
| Fatality Rate | High (up to 50% for HPS) | Generally low (variable by variant/age) |
| Pandemic Risk | Low (contained outbreaks) | High (global pandemic) |
The Clinical Picture: Leaky Lungs vs. Tissue Destruction
From a medical standpoint, the way these two viruses attack the body is fundamentally different. COVID-19 replicates rapidly in the respiratory system, often causing direct damage to lung tissue and triggering a systemic inflammatory response.
The Andes virus operates on a different timeline, and mechanism. It primarily causes Hantavirus Pulmonary Syndrome (HPS). Interestingly, the breathing difficulties associated with HPS aren’t caused by the virus shredding the lungs. Instead, the virus causes dysfunction in the blood vessels and triggers a delayed immune response. This causes the capillaries in the lungs to become “leaky,” allowing fluid to seep into the alveolar spaces. Essentially, the patient’s own immune response leads to pulmonary edema, making it nearly impossible to oxygenate the blood.
This progression is slower and more idiosyncratic than COVID-19. This is why the World Health Organization (WHO) recommends a monitoring period of up to 42 days after exposure. This window doesn’t mean a person is infectious for six weeks; rather, it reflects the outer limit of the incubation period. Because the virus progresses slowly, a PCR test taken too early may return a false negative because there isn’t enough genetic material yet to detect. This is why the Doherty Institute in Melbourne is utilizing a combination of PCR testing and serology—blood-based antibody testing—to ensure no case is missed.
The Modern Scientific Response
While there is currently no licensed vaccine or specific antiviral drug for the Andes virus, the global medical community’s response to this outbreak has been remarkably swift. Treatment remains supportive, focusing on intensive monitoring, respiratory support, and managing kidney and heart complications.
The real victory here is in genomic surveillance. Almost immediately after the outbreak began, Swiss laboratories collaborated to sequence the complete genetic code of the virus from a patient and released it to the public. In the early days of 2020, this level of transparency and speed was a struggle. Today, having a reference genome within days allows researchers worldwide to instantly identify the strain and track its movement, significantly narrowing the window for potential spread.
The bottom line is that a virus does not become a pandemic simply because it is deadly. In fact, viruses with extremely high fatality rates often burn themselves out quickly because they kill their hosts before they can be widely transmitted. The Andes virus is dangerous to the individual, but it is a poor candidate for a global catastrophe.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.
Public health officials are now awaiting the results of the ongoing monitoring of the repatriated passengers. The next critical checkpoint will be the completion of the initial three-week quarantine period for the returning travelers, after which the Australian Department of Health is expected to provide an update on the status of the monitored individuals and any further serological findings.
Do you have questions about zoonotic viruses or how public health monitoring works? Share your thoughts in the comments or share this article to help spread accurate medical information.
